Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer.
Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies.
In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited.
POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
As of December 27, 2023, POINT Biopharma Global Inc. operates as a subsidiary of Eli Lilly and Company.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.23 Increased by +11.54% | -0.30 Increased by +23.33% |
| Aug 14, 23 | -0.24 Increased by +11.11% | -0.29 Increased by +17.24% |
| May 15, 23 | -0.16 Increased by +11.11% | -0.31 Increased by +48.39% |
| Mar 27, 23 | 1.53 Increased by +1.06 K% | -0.26 Increased by +688.46% |
| Nov 14, 22 | -0.26 Decreased by -36.84% | -0.28 Increased by +7.14% |
| Aug 12, 22 | -0.27 Decreased by -80.00% | -0.22 Decreased by -22.73% |
| May 13, 22 | -0.18 Decreased by -125.00% | -0.21 Increased by +14.29% |
| Mar 25, 22 | -0.16 Decreased by -1.50 K% | -0.23 Increased by +30.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 2.79 M Increased by +N/A% | -24.77 M Decreased by -3.17% | Decreased by -887.97% Decreased by N/A% |
| Jun 30, 23 | 4.87 M Increased by +N/A% | -25.41 M Decreased by -3.38% | Decreased by -522.23% Decreased by N/A% |
| Mar 31, 23 | 9.46 M Increased by +N/A% | -16.53 M Decreased by -0.92% | Decreased by -174.79% Decreased by N/A% |
| Dec 31, 22 | 226.58 M Increased by +N/A% | 163.27 M Increased by +1.25 K% | Increased by +72.06% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -24.01 M Decreased by -40.29% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -24.58 M Decreased by -179.17% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -16.38 M Decreased by -183.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -14.20 M Decreased by -155.76% | Decreased by N/A% - |